Catalog No.
RGK11202
Description
Chimeric P3 antibody specifically reacted with GM3(NeuGc) and GM2(NeuGc) gangliosides, and not with their acetylated variants.The chimeric antibody chP3 selectively recognizes a broad variety of NeuGc gangliosides, showing no cross-reactivity to the highly similar N-acetylated (NeuAc) gangliosidesWe have further investigated the interaction of chP3 with its anti-idiotypic antibody, 1E10 (also known as Racotumomab), currently in clinical trials as a cancer vaccine.
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
NeuGcGM3, Ganglioside N-glycolyl GM3, N-glycolylneuraminic acid -NeuGc, NGNA-GM3 ganglioside, NeuGcGM3
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
ChEBI ID： 84118
Applications
ELISA, IHC
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
chP3
Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. PMID: 19748674
Monoclonal antibody specific to alpha-2-->3-linked deaminated neuraminyl beta-galactosyl sequence. PMID: 8448384
Generation and characterization of an anti-idiotype monoclonal antibody related to GM3(NeuGc) ganglioside. PMID: 14678648
Cancer vaccines: an update with special focus on ganglioside antigens. PMID: 11836591
Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions. PMID: 14511569
Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody. PMID: 21306777
Gangliosides, Ab1 and Ab2 antibodies I. Towards a molecular dissection of an idiotype-anti-idiotype system. PMID: 16581129
Anti-GM3-lactam monoclonal antibodies of the IgG type recognize natural GM3-ganglioside lactone but not GM3-ganglioside. PMID: 1305422
Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. PMID: 9890708
Insights into the immunogenetic basis of two ganglioside-associated idiotypic networks. PMID: 17270710
Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: A self versus non-self-matter. PMID: 16076030
Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides. PMID: 9621110
Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody PMID: 19748674
Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment., PMID:34516533
Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas., PMID:31182063
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients., PMID:29936534
Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy., PMID:28604556
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications., PMID:27449755
Racotumomab for treating lung cancer and pediatric refractory malignancies., PMID:26903265
Anti-NeuGcGM3 reactivity: a possible role of natural antibodies and B-1 cells in tumor immunosurveillance., PMID:26214505
A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies., PMID:26154941
Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer., PMID:25420897
Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 Ganglioside in retinoblastoma tumours., PMID:25403557
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer., PMID:24918647
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients., PMID:24788102
Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3., PMID:23335925
Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties., PMID:23319307
Immune response to racotumomab in a child with relapsed neuroblastoma., PMID:23267436
Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer., PMID:23162791
Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data., PMID:23110257
Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma., PMID:23055778
NGlycolylGM3/VSSP Vaccine in Metastatic Breast Cancer Patients: Results of Phase I/IIa Clinical Trial., PMID:23055739
N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese., PMID:22574836
P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties., PMID:22566972
Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms., PMID:22363862
Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System., PMID:21991524
Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer., PMID:21941577
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism., PMID:21300821
Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients., PMID:20855939
Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines., PMID:19951433
Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody., PMID:19748674
Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry., PMID:19435393
Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma., PMID:19066887
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody., PMID:18941253
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study., PMID:18285705
Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial., PMID:17218777
Incorporation, remodeling and re-expression of exogenous gangliosides in human cancer cell lines in vitro and in vivo., PMID:15279066
Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides., PMID:12763476
Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine., PMID:12637465
Lack of antibody production against Hanganutziu-Deicher (H-D) antigens with N-glycolylneuraminic acid in patients with porcine exposure history., PMID:11021662
Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides., PMID:9621110
Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids., PMID:8770642
Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside., PMID:8597625
The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process., PMID:2464027
Analysis of the expression of N-glycolylneuraminic acid-containing gangliosides in cells and tissues using two human monoclonal antibodies., PMID:3192544
Antiglycolipid antibodies in normal and pathologic human sera and synovial fluids., PMID:4060695
For research use only. Not for human or drug use.
